Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)

BACKGROUND: Clinical trials have shown cardiovascular benefits and potential risks from sodium glucose cotransporter 2 inhibitors (SGLT2i). Trials may have limited ability to address individual end points or safety concerns. METHODS: We performed a population-based cohort study among patients with t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Circulation
Autors principals: Udell, Jacob A., Yuan, Zhong, Rush, Toni, Sicignano, Nicholas M., Galitz, Michael, Rosenthal, Norman
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2018
Matèries:
Original Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5895161/
https://ncbi.nlm.nih.gov/pubmed/29133607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.117.031227
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars